Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROR1 | Q01973 | 5/20 | 0.67 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 14/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640182 | 0.89 | ABL1 (0.74) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16644588 | 0.85 | ABL1 (0.76) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16644458 | 0.81 | ABL1 (0.71) | ROR1CSF1RABL1 | |
| SCHEMBL16644584 | 0.81 | ABL1 (0.79) | ROR1CSF1RABL1 | |
| SCHEMBL19317721 | 0.79 | ROR1 (0.79) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16644466 | 0.77 | CSF1R (0.75) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16644461 | 0.77 | ABL1 (0.84) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16644460 | 0.76 | ABL1 (0.68) | CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL16250614 | 0.76 | ABL1 (0.80) | ROR1CSF1RABL1CYP3A4KCNH2 | |
| SCHEMBL18298082 | 0.76 | ABL1 (0.80) | ROR1CSF1RABL1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ROR1 263/4885CSF1R 2599/4885ABL1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.